Enanta Pharmaceuticals Inc (ENTA) is trading up at $11.62 (+2.74%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
| FY2016Sep 2016 | FY2017Sep 2017 | FY2018Sep 2018 | FY2019Sep 2019 | FY2020Sep 2020 | FY2021Sep 2021 | FY2022Sep 2022 | FY2023Sep 2023 | FY2024Sep 2024 | FY2025Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $88.3M | $102.8M | $206.6M | $205.2M | $122.5M | $97.1M | $86.2M | $79.2M | $67.6M | $65.3M |
| Growth (year over year) | −45.1% | +16.5% | +101.0% | −0.7% | −40.3% | −20.7% | −11.2% | −8.1% | −14.6% | −3.4% |
| Operating income | $30.8M | $24.6M | $88.3M | $36.7M | −$41.6M | −$109.6M | −$123.8M | −$137.2M | −$121.7M | −$85.3M |
| Operating margin | 34.9% | 23.9% | 42.7% | 17.9% | −34.0% | −112.9% | −143.7% | −173.2% | −179.9% | −130.7% |
| Net income | $21.7M | $17.7M | $72.0M | $46.4M | −$36.2M | −$79.0M | −$121.8M | −$133.8M | −$116.0M | −$81.9M |
| Net margin | 24.5% | 17.2% | 34.8% | 22.6% | −29.5% | −81.4% | −141.3% | −169.0% | −171.6% | −125.4% |
| EPS (diluted) | $1.13 | $0.91 | $3.48 | $2.21 | −$1.81 | −$3.92 | −$5.91 | −$6.38 | −$5.48 | −$3.84 |
| Balance sheet | ||||||||||
| Cash and equivalents | $16.6M | $65.7M | $63.9M | $51.2M | $87.1M | $57.2M | $44.0M | $85.4M | $37.2M | $32.3M |
| Total assets | $281.3M | $326.6M | $414.2M | $489.8M | $486.1M | $438.8M | $375.4M | $462.3M | $376.7M | $280.7M |
| Total liabilities | $11.3M | $25.0M | $20.5M | $27.3M | $30.6M | $39.4M | $54.1M | $245.5M | $247.8M | $216.0M |
| Shareholders' equity | $269.9M | $301.7M | $393.7M | $462.5M | $455.6M | $399.4M | $321.3M | $216.7M | $128.8M | $64.7M |
| Cash flow | ||||||||||
| Operating cash flow | $35.8M | $52.7M | $29.2M | $71.4M | $7.09M | −$70.0M | −$84.8M | −$103.2M | −$78.8M | −$19.3M |
| Capital expenditure | $4.74M | $2.51M | $2.98M | $5.42M | $1.45M | $750.0K | $2.13M | $9.06M | $17.9M | $12.9M |
| Free cash flow | $31.1M | $50.1M | $26.2M | $66.0M | $5.64M | −$70.7M | −$86.9M | −$112.2M | −$96.7M | −$32.2M |
| Q4 FY24†Sep 2024 | Q1 FY25Dec 2024 | Q2 FY25Mar 2025 | Q3 FY25Jun 2025 | Q4 FY25†Sep 2025 | Q1 FY26Dec 2025 | Q2 FY26Mar 2026 | Q3 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $14.6M | $17.0M | $14.9M | $18.3M | $15.1M | $18.6M | $17.2M | $14.4M |
| Growth (year over year) | −22.8% | −5.8% | −12.5% | +1.9% | +3.5% | +9.8% | +15.0% | −21.6% |
| Operating income | −$29.9M | −$23.5M | −$24.5M | −$18.9M | −$18.4M | −$11.3M | −$11.9M | −$17.2M |
| Operating margin | −204.4% | −138.8% | −164.3% | −103.2% | −121.6% | −60.5% | −69.1% | −120.0% |
| Net income | −$28.8M | −$22.3M | −$22.6M | −$18.3M | −$18.7M | −$11.9M | −$13.1M | −$19.5M |
| Net margin | −197.3% | −131.4% | −151.7% | −99.7% | −123.6% | −64.1% | −76.3% | −135.8% |
| EPS (diluted) | −$1.36 | −$1.05 | −$1.06 | −$0.85 | −$0.88 | −$0.42 | −$0.45 | −$0.67 |
| Balance sheet | ||||||||
| Cash and equivalents | $37.2M | $84.3M | $60.2M | $44.8M | $32.3M | $37.4M | $34.9M | $33.4M |
| Total assets | $376.7M | $348.6M | $323.0M | $301.0M | $280.7M | $329.5M | $314.7M | $296.9M |
| Total liabilities | $247.8M | $236.8M | $229.5M | $221.8M | $216.0M | $202.9M | $198.1M | $195.8M |
| Shareholders' equity | $128.8M | $111.8M | $93.5M | $79.3M | $64.7M | $126.6M | $116.6M | $101.1M |
| Cash flow | ||||||||
| Operating cash flow | −$10.4M | −$16.8M | −$13.5M | $17.5M | −$6.49M | −$11.7M | −$7.16M | −$9.97M |
| Capital expenditure | $8.95M | $8.74M | $2.54M | $155.0K | $1.46M | $143.0K | $15.0K | $7.00K |
| Free cash flow | −$19.4M | −$25.5M | −$16.0M | $17.4M | −$7.95M | −$11.8M | −$7.17M | −$9.98M |
From Enanta Pharmaceuticals Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in September. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Enanta Pharmaceuticals Inc in our feed yet.